ScholarIQanswers from OpenAlex & ORCID
David J. Lockhart
ResearcherPublications, citations & collaboration network
David J. Lockhart is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does David J. Lockhart have?
ScholarIQindexed works
David J. Lockhart has 156 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does David J. Lockhart have?
ScholarIQcitation count
David J. Lockhart has 33,281 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of David J. Lockhart?
ScholarIQh-index
David J. Lockhart has an h-index of 61 in OpenAlex.
What is the i10-index of David J. Lockhart?
ScholarIQi10-index
David J. Lockhart has an i10-index of 86 in OpenAlex.
What is the OpenAlex record for David J. Lockhart?
ScholarIQopenalex
The OpenAlex for David J. Lockhart is on the source record.
What are the most-cited papers on David J. Lockhart?
ScholarIQmost cited works
Functional Characterization of the <i>S. cerevisiae</i> Genome by Gene Deletion and Parallel Analysis
Elizabeth A. Winzeler, Daniel Shoemaker, Anna Astromoff, Hong Liang, Keith M. Anderson, Bruno André, Rhonda Bangham, Rocío Benito, Jef D. Boeke, Howard Bussey, Angela Chu, Carla J. Connelly, Karen Davis, Fred S. Dietrich, Sally Dow, Mohamed El Bakkoury, Françoise Foury, Stephen Friend, Erik Gentalen, Guri Giaever, Johannes H. Hegemann, Ted Jones, Michael T. Laub, Hong Liao, Nicole Liebundguth, David J. Lockhart, Anca Lucau‐Danila, Marc Lussier, Nasiha M’Rabet, P Ménard, Michael Mittmann, Chai Pai, Corinne Rebischung, José Luis Revuelta, Linda Riles, Christopher J. Roberts, Petra Ross‐Macdonald, Bart Scherens, M Snyder, Sharon Sookhai-Mahadeo, Reginald Storms, Steeve Véronneau, Marleen Voet, Guido Volckaert, Teresa R. Ward, Robert Wysocki, Grace S. Yen, Kexin Yu, Katja Zimmermann, Peter Philippsen, Mark Johnston, Ronald W. Davis
Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer
John Welsh, Patrick P. Zarrinkar, Lisa M. Sapinoso, S Kern, Cynthia Behling, Bradley J. Monk, David J. Lockhart, Robert A. Burger, Garret M. Hampton
Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat
Dominique P. Germain, Derralynn Hughes, Kathy Nicholls, Daniel G. Bichet, Roberto Giugliani, William R. Wilcox, Claudio Feliciani, Suma P. Shankar, Fatih Süheyl Ezgü, Hernan Amartino, Drago Bratkovic, Ulla Feldt‐Rasmussen, Khan Nedd, Usama Sharaf El Din, Charles Marques Lourenço, Maryam Banikazemi, Joel Charrow, Majed Dasouki, David N. Finegold, Pilar Giraldo, Özlem Göker-Alpan, Nicola Longo, C. Ronald Scott, Roser Torrá, Ahmad Tuffaha, Ana Jovanović, Stephen Waldek, Seymour Packman, Elizabeth Ludington, Christopher Viereck, John Kirk, Julie Yu, Elfrida R. Benjamin, Franklin K. Johnson, David J. Lockhart, Nina Skuban, Jeff Castelli, Jay Barth, Carrolee Barlow, Raphael Schiffmann
Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study
Derralynn Hughes, Kathy Nicholls, Suma P. Shankar, Gere Sunder–Plassmann, David M. Koeller, Khan Nedd, Gerard Vockley, Takashi Hamazaki, Robin Lachmann, Toya Ohashi, Iacopo Olivotto, Norio Sakai, Patrick Deegan, David Dimmock, François Eyskens, Dominique P. Germain, Özlem Göker-Alpan, É. Hachulla, Ana Jovanović, Charles Marques Lourenço, Ichiei Narita, Mark Thomas, William R. Wilcox, Daniel G. Bichet, Raphael Schiffmann, Elizabeth Ludington, Christopher Viereck, John Kirk, Julie Yu, Franklin K. Johnson, Pol Boudes, Elfrida R. Benjamin, David J. Lockhart, Carrolee Barlow, Nina Skuban, Jeffrey P. Castelli, Jay Barth, Ulla Feldt‐Rasmussen